Undisclosed E3 ubiquitin-protein ligase

The term 'Undisclosed E3 ubiquitin-protein ligase' is a placeholder designation frequently encountered in pharmaceutical research and patent filings to refer to a specific member of the E3 ligase family whose identity is kept confidential for proprietary reasons. E3 ligases are essential components of the ubiquitin-proteasome system (UPS), acting as substrate-recognition modules that catalyze the transfer of ubiquitin from an E2 enzyme to a specific target protein, thereby flagging it for degradation by the 26S proteasome (Berndsen & Wolberger, 2014). In modern drug discovery, these ligases are central to Targeted Protein Degradation (TPD) technologies, such as Proteolysis-Targeting Chimeras (PROTACs), which recruit an E3 ligase to a protein of interest to trigger its destruction (Mullard, 2019). While well-characterized ligases like Cereblon (CRBN) and Von Hippel-Lindau (VHL) are widely used, the pursuit of undisclosed ligases often aims to achieve better tissue specificity, reduced systemic toxicity, or to overcome resistance mechanisms associated with established ligases (Békés et al., 2022). Consequently, the biological impact and safety profile of an undisclosed E3 ligase are entirely dependent on the specific, unnamed protein's unique physiological role and expression pattern (Ishida & Ciulli, 2021). These targets are particularly valuable for degrading 'undruggable' proteins, such as transcription factors or scaffolding proteins, which lack traditional enzymatic pockets.

Other names

Novel E3 ligaseProprietary E3 ligaseUnspecified E3 ubiquitin ligase

Recruitment of the E3 ligase to a target protein via a bifunctional degrader (e.g., PROTAC) to induce polyubiquitination and subsequent proteasomal degradation.